WEIGUANG BIOLOGICAL(002880) Xin Lang Cai Jing·2025-04-27 00:36Group 1: Financial Performance - In 2024, the company achieved operating revenue of 1.203 billion (up 14.75%) and net profit attributable to shareholders of 254 million (up 15.95%) [1] - For Q4 2024, operating revenue was 349 million (up 11.51%) and net profit attributable to shareholders was 71 million (up 5.05%) [1] - In Q1 2025, the company reported operating revenue of 225 million (down 0.57%) and net profit attributable to shareholders of 44 million (down 6.54%) [1] Group 2: Plasma Collection and Product Development - In 2024, the company’s nine single plasma collection stations achieved a plasma collection volume of 562 tons (up 8.7%) [2] - The blood products business generated revenue of 1.071 billion (up 8.8%) with a gross margin of 43.04% (up 2.28 percentage points) [2] - The company obtained a drug registration certificate for prothrombin complex in May 2024, expanding its product range to 11 varieties across three categories [2] Group 3: Real Estate and Industry Development - In 2024, the company’s property rental business generated revenue of 121 million (up 250.44%) with a gross margin of 28.5% (up 11.32 percentage points) [3] - The company is developing a life sciences park focusing on synthetic biology and brain science, attracting high-quality enterprises in the biopharmaceutical sector [3] Group 4: Profit Forecast and Investment Recommendation - The company forecasts revenues of 1.288 billion, 1.415 billion, and 1.572 billion for 2025, 2026, and 2027 respectively, with net profits of 278 million, 317 million, and 369 million [4] - The corresponding price-to-earnings ratios are projected to be 23.1, 20.3, and 17.4 [4]